High Throughput 96- & 384-Well DNA Purificati?on
MagSi-DNA cleanFIX from AMSBIO offers a cost effective solution for purifying DNA fragments, removing all unwanted side products and reagents, such as single nucleotides, terminator dyes, primers and primer dimers, enzymes, buffers and salts.
In many genomics applications, purification of DNA fragments is required to prevent downstream interference with analysis methods. Purification of PCR reactions often requires removal of dNTPs, primers, enzymes, salt by-products and various additives. Historically purification protocols have involved different sample types, different volumes and often multiple washing and centrifugation steps. Using such methods the errors incurred during sample preparation have resulted in lost time and significant costs due to re-work and lost reagents.
MagSi-DNA cleanFIX enables a combination of PCR clean-up and dye terminator removal from sequence reaction mixes with a single product. The kit uses magnetic silica bead technology, and is easily automated because no columns or centrifugation steps are involved. The kit uses a simple “Bind, Wash & Elute” procedure common to magnetic particle purification protocols.
Independent test results demonstrate how MagSi-DNA cleanFIX purification methods developed for a commercial liquid handling workstation provide an automated walk-away solution for PCR clean-up and dye terminator removal from sequence reactions. The precision and reproducibility of the workstation in combination with the customized magnets for MagSi-DNA cleanFIX are shown to allow fast magnetic separation and homogenization of the samples. Overall the PCR clean-up protocol using MagSi-DNA cleanFIX is shown to enable fast and efficient recovery of DNA fragments larger than 80 bp with >99% removal of primers and primer dimers. In addition the dye terminator removal method consistently delivered high quality sequence data with Phred >20 scores above 700.
For further information on MagSi-DNA cleanFIX and the fully range of magnetic beads available from AMSBIO please visit www.amsbio.com/DNA-sequencing-
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance